<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ropinirole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ropinirole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ropinirole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11034" href="/d/html/11034.html" rel="external">see "Ropinirole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F219144"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Requip XL [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868190"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Ropinirole;</li>
<li>PMS-Ropinirole [DSC];</li>
<li>RAN-Ropinirole;</li>
<li>TEVA-Ropinirole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F219173"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F219148"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afdbcf58-54a4-4f1f-8310-d12811c549e2">Parkinson disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease</b>
<b>(monotherapy or adjunctive therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.25 mg 3 times daily; may increase <b>daily</b> dose based on response and tolerability. For doses up to 3 mg/day, may increase <b>daily</b> dose by 0.75 mg every 7 days; for doses from 3 to 9 mg/day, may increase <b>daily</b> dose by 1.5 mg every 7 days; for doses &gt;9 mg/day, may increase <b>daily</b> dose by 3 mg every 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose: 24 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spindler.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spindler.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Usual dose: 12 to 16 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spindler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spindler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 2 mg once daily for 1 to 2 weeks; may increase <b>daily</b> dose by 2 mg at weekly or longer intervals based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum dose: 24 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17404192','lexi-content-ref-18768106','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17404192','lexi-content-ref-18768106','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Usual dose: 12 to 16 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spindler.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spindler.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Converting from ropinirole immediate release to ropinirole extended release:</i> May initiate extended release the morning after the last immediate release evening dose is taken. The total daily dose should remain the same.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 0.25 mg once daily 1 to 3 hours before bedtime. Dose may be increased after 2 days to 0.5 mg once daily, and after 7 days to 1 mg once daily. Dose may be further increased in 0.5 mg increments every week until reaching 3 mg once daily during week 6. Dose may be increased to a maximum of 4 mg/day beginning week 7 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Alternatively, some experts recommend increasing by 0.25 mg every 2 to 3 days based on response and tolerability to lowest effective dose, up to a maximum of 4 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Silber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Silber.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If augmentation occurs (worsening symptoms during dopaminergic therapy), dose earlier in the evening, divide into multiple evening doses, increase dose (keeping at or below 4 mg/day), or consider switching to alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27448465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27448465'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Discontinuation of therapy: </b>Do not discontinue abruptly; gradually taper over 7 days. For IR formulation, some patients may tolerate a reduction in frequency of administration from 3 times daily to twice daily for 4 days, then once daily for the remaining 3 days.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991650"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11069211','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11069211','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, the following doses are recommended (based on pharmacokinetic data in patients on hemodialysis):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Restless legs syndrome:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release:</b> Initial: 0.25 mg once daily; may titrate dose upward gradually based on tolerability and response at intervals greater than or equal to those recommended for patients with normal kidney function (maximum dose: 3 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Parkinson disease:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Immediate release:</b> Initial: 0.25 mg 3 times daily; may titrate dose upward gradually based on tolerability and response at intervals greater than or equal to those recommended for patients with normal kidney function (maximum dose: 18 mg/day in 3 divided doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Extended release: </b>Initial: 2 mg once daily; may titrate dose upward gradually based on tolerability and response at intervals greater than or equal to those recommended for patients with normal kidney function (maximum dose: 18 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly removed by hemodialysis (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Restless legs syndrome:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release:</b> Initial: 0.25 mg once daily; may titrate dose upward gradually based on tolerability and response at intervals ≥ to those recommended for patients with normal kidney function (maximum dose: 3 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); studies in this population utilized ≤2 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24024727','lexi-content-ref-15319704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24024727','lexi-content-ref-15319704'])">Ref</a></span>). Postdialysis supplemental doses are not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parkinson disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release:</b> Initial: 0.25 mg 3 times daily; may titrate dose upward based on tolerability and response (maximum dose: 18 mg/day in 3 divided doses); postdialysis supplemental doses are not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Extended release: </b>Initial: 2 mg once daily; may titrate dose upward based on tolerability and response (maximum dose: 18 mg/day); postdialysis supplemental doses are not required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly removed by peritoneal dialysis (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Restless legs syndrome:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release</b>
<b>:</b> Initial: 0.25 mg once daily; may titrate dose upward gradually based on tolerability and response at intervals greater than or equal to those recommended for patients with normal kidney function (maximum dose: 3 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parkinson disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immediate release:</b> Initial: 0.25 mg 3 times daily; may titrate dose upward based on tolerability and response (maximum dose: 18 mg/day in 3 divided doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Extended release: </b>Initial: 2 mg once daily; may titrate dose upward based on tolerability and response at intervals greater than or equal to those recommended for patients with normal kidney function (maximum dose: 18 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Unlikely to be significantly removed by CRRT (large V<sub>d</sub>). Dose as if the patient has a CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Unlikely to be significantly removed by PIRRT (large V<sub>d</sub>). Dose as if the patient has a CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988952"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Titrate with caution.</p></div>
<div class="block doe drugH1Div" id="F219149"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F56391300"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Augmentation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Augmentation, a worsening of symptoms beyond the level of severity that was experienced when the medication was initiated, has been reported with dopamine agonists such as ropinirole, in patients with restless leg syndrome (RLS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22328464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22328464'])">Ref</a></span>). In addition to severity, the symptoms occur at an earlier time of day compared to pretreatment timing of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26106453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26106453'])">Ref</a></span>). A pooled meta-analysis reported an overall augmentation rate of 5.6% in RLS with treatment (not specifically with ropinirole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>). Historically, treatment with levodopa has been associated with the highest rate followed by dopamine agonists, such as ropinirole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>). In one study with ropinirole alone, augmentation occurred in up to 4% and was clinically meaningful in most cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22328464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22328464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; not clearly established. Proposed mechanisms include increased dopamine concentrations in the CNS and overstimulation of the dopamine D<sub>1</sub> receptors compared to dopamine D<sub>2</sub> receptors in the spinal cord (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987735'])">Ref</a></span>). Iron deficiency may also reduce the function of the dopamine transporter, increasing dopamine concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987735'])">Ref</a></span>). In addition, augmentation may also result from dopamine receptor down-regulation, which lowers tolerance to dopaminergic effects in a circadian manner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33880737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33880737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Onset: Delayed; usually after months of treatment (mean duration 8.8 months in one study with pramipexole) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14725821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14725821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466','lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466','lexi-content-ref-16987735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-26765466'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• More severe RLS prior to treatment (may be related to higher dose use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-14725821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-14725821'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Iron deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004','lexi-content-ref-16987735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004','lexi-content-ref-16987735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28818004']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28818004'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of IR formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26765466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26765466'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Impulse control and related disorders</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ropinirole has been associated with <b>impulse control disorders </b>and related disorders, manifesting as <b>pathological gambling</b>, <b>increased libido</b> (hypersexuality), compulsive or binge buying/eating, and/or other intense urges. The prevalence of impulsive control was reported to range from 2.6% to 34.8% in Parkinson disease (PD). A lower prevalence was reported in patients taking dopamine agonists, such as ropinirole, for restless leg syndrome (RLS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>). Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Possibly dose-related; may be due to activation of dopamine receptors (mostly D<sub>3</sub>) involved in both the nigrostriatal and the reward pathways (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Difficult to determine. In one study, the incidence of impulsive behavior was relatively low during the first 30 months of exposure but higher over the next 30 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27425586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27425586'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher affinity for D<sub>3</sub> receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (for PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of psychiatric symptoms (eg, anxiety and depression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of impulse control disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Earlier onset of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28861870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28861870'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31700703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31700703'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nausea and vomiting</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea</b> and <b>vomiting</b> are known side effects of dopamine agonists, such as ropinirole.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; may be related to direct D<sub>2</sub> receptor agonism within the chemoreceptor trigger zone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Commonly seen in early phase of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9617508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9617508'])">Ref</a></span>). It is important to note that reports of nausea and vomiting in studies may be subject to recall bias; so, it is unclear whether the onset of symptoms occurred with the first doses or required weeks of therapy prior to onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors (possible):</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Administration on an empty stomach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9578193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9578193'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of IR formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383607'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension and syncope</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ropinirole may cause <b>orthostatic hypotension</b>. Patients with Parkinson disease (PD) may have an impaired capacity to respond to a postural change due to neurodegenerative processes in the brain stem. Orthostatic hypotension may be asymptomatic or symptomatic, leading to <b>dizziness</b> and <b>falling </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>). <b>Syncope</b>, sometimes associated with <b>bradycardia</b>, has also been observed in association with ropinirole in early Parkinson disease patients and patients with restless leg syndrome (RLS).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Primarily by venous and arterial dilation through inhibition of the sympathetic nervous system (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any point during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11030798'])">Ref</a></span>). Most cases occurred more than 4 weeks after initiation and may occur more often with initiation of therapy or dose escalation. <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Initiation of therapy or dose escalation</p>
<p style="text-indent:-2em;margin-left:6em;">• Autonomic dysfunction (as with PD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that may cause orthostatic hypotension (eg, antihypertensive or antiarrhythmic medications, diuretics, levodopa, monoamine oxidase inhibitors, tricyclic antidepressants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-11030798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (eg, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212','lexi-content-ref-11030798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212','lexi-content-ref-11030798'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger patients with asthenic features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31456212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31456212'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychotic-like behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Ropinirole may cause or exacerbate behavioral changes, including <b>psychotic symptoms</b> (eg, <b>paranoid ideation</b>, <b>hallucination</b>, <b>delusion</b>, <b>confusion</b>, <b>mania</b>, <b>disorientation</b>, <b>aggressive behavior,</b>
<b>agitation</b>, <b>delirium</b>). In a prospective comparison of levodopa versus ropinirole treatment, ropinirole demonstrated a higher incidence of hallucinations compared to levodopa (17% vs 6%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10816186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10816186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and duration-related; ropinirole is a non-ergot D<sub>2</sub>/D<sub>3</sub> dopamine agonist with greatest affinity for D<sub>3</sub> receptors. Psychosis is thought to result from some degree of D<sub>2</sub> receptor stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21494343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21494343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Hallucinations typically occurred more frequently in adjunct studies versus early therapy studies for Parkinson disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9617508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9617508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9617508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9617508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9617508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9617508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbid cognitive impairment or dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515253'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (hallucinations)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of hallucinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9617508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9617508'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Number of comorbidities and concurrent medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19515253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19515253'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Somnolence and sleep attacks</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Somnolence (<b>drowsiness</b>) is an adverse reaction of dopamine agonists, including ropinirole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>). Patients taking ropinirole may experience sleep attacks (<b>sudden onset of sleep</b>), defined as sudden, irresistible, overwhelming sleepiness without awareness of falling sleep (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>). Conversely, studies in patients with restless leg syndrome (RLS) found that ropinirole may improve sleep adequacy, quantity, and sleep disturbance, and reduce daytime somnolence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19249945','lexi-content-ref-14707315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19249945','lexi-content-ref-14707315'])">Ref</a></span>). Sleep attacks may also occur in patients with Parkinson disease (PD) in the absence of dopaminergic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Likely multifactorial; related to modulation of dopamine receptors, specifically D<sub>3</sub> agonist activity. May also be the result of increased dopamine, leading to down regulation of dopaminergic input to the reticular activating system. Genetic polymorphisms in dopamine receptors may play a role (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; some cases have occurred more than a year after initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer treatment duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression in patients with PD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11798367']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11798367'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Disease duration &lt;7 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &lt;70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30363881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30363881'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of sleep disorders (other than RLS)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol or medications that may cause sedation or increase ropinirole plasma levels</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dopamine agonist <b>withdrawal syndrome</b> (DAWS) has been defined as a stereotyped cluster of physical and psychological symptoms that may be mild, moderate, or severe. Psychiatric symptoms may include <b>anxiety,</b> panic attacks, <b>depression</b>, irritability, <b>agitation,</b> dysphoria, agoraphobia, <b>insomnia</b>, drug cravings, and <b>pain.</b> Physical symptoms may include <b>diaphoresis,</b>
<b>flushing, nausea, fatigue, orthostatic</b>
<b>hypotension,</b> and <b>vomiting</b>. Psychiatric symptoms are the most common and prominent symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30713891','lexi-content-ref-20065130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30713891','lexi-content-ref-20065130'])">Ref</a></span>). DAWS has been reported mainly in Parkinson disease, where it affects about 15% to 19% of patients who taper or discontinue a dopamine agonist (Yu 2017). Some recent case reports have identified this syndrome in patients with restless leg syndrome as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24078717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24078717'])">Ref</a></span>). Symptoms may be self-limited or protracted, lasting for months to years (Yu 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Exact mechanism unknown; may be dose- and duration-related. May be due to sudden changes in dopaminergic stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22993451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22993451'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during taper or after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher daily doses (≥7.5 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative exposure to dopamine agonists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of impulse control disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20065130','lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20065130','lexi-content-ref-28104232'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of deep brain stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28104232']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28104232'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F219118"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling as reported with the immediate-release (IR) and extended-release (ER) formulations. IR data are inclusive of trials in early Parkinson disease (PD) without levodopa and restless legs syndrome (RLS). Extended-release (ER) data are from trials in early PD without levodopa.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (IR: PD: 5%; ER: 3% to 15%), hypotension (IR: PD: 2%, RLS: ≤25%), orthostatic hypotension (IR: PD: 6%, RLS: ≤25%; ER: 14%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension')">table 1</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension</span>, syncope (IR: PD: 12%, RLS: 1% to 2%; ER: &lt;1%; sometimes associated with bradycardia)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension" frame="border" id="lexi-content-orthostatic-hypotension" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Orthostatic Hypotension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Decrease in standing systolic blood pressure of ≥20 mm Hg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">27</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hypotension or orthostatic hypotension</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (IR: PD: 60%, RLS: 40%; ER: 8% to 33%)<span class="lexi-table-link-container"> (<a aria-label="Nausea table link" class="lexi-table-link" data-table-id="lexi-content-nausea" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-nausea')">table 2</a>)</span><span class="table-link" style="display:none;">Nausea</span>, vomiting (IR: PD: 12%, RLS: 11%; ER: ≤10%)<span class="lexi-table-link-container"> (<a aria-label="Vomiting table link" class="lexi-table-link" data-table-id="lexi-content-vomiting" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-vomiting')">table 3</a>)</span><span class="table-link" style="display:none;">Vomiting</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Nausea" frame="border" id="lexi-content-nausea" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Nausea</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">60%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">33%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Vomiting" frame="border" id="lexi-content-vomiting" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Vomiting</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Infection: Viral infection (IR: PD: 11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (IR: PD: 40%, RLS: 11%; ER: ≤10%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 4</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (IR: PD: 40%, RLS: 12%; ER: 8% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 5</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, fatigue (IR: PD: ≤16%, RLS: ≤9%), headache (ER: 5% to 15%), malaise (IR: PD: ≤16%, RLS: ≤9%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">40%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Restless legs syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">496</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (IR: PD: ≤16%, RLS: ≤9%), back pain (ER: 5% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (IR: PD: 2%), chest pain (IR: PD: 4%), extrasystoles (IR: PD: 2%), flushing (IR: PD: 3%), lower extremity edema (IR: PD: 7%), palpitations (IR: PD: 3%), peripheral edema (IR: RLS: 2%), peripheral ischemia (IR: PD: 3%), tachycardia (IR: PD: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (IR: PD: 6%), hyperhidrosis (IR: RLS: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dependent edema (IR: PD: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (IR: PD: 6%; ER: 7%), anorexia (IR: PD: 4%), constipation (ER: 5%), diarrhea (IR: RLS: 5%), dyspepsia (IR: PD: 10%, RLS: 4%), flatulence (IR: PD: 3%), upper abdominal pain (IR: RLS: 3%), xerostomia (IR: PD: 5%, RLS: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (IR: PD: 3%), urinary tract infection (IR: PD: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (IR: PD: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (IR: RLS: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amnesia (IR: PD: 3%), confusion (IR: PD: 5%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 6</a>)</span><span class="table-link" style="display:none;">Confusion</span>, hallucination (IR: PD: 5%)<span class="lexi-table-link-container"> (<a aria-label="Hallucination table link" class="lexi-table-link" data-table-id="lexi-content-hallucination" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hallucination')">table 7</a>)</span><span class="table-link" style="display:none;">Hallucination</span>, hypoesthesia (IR: PD: 4%), lack of concentration (IR: PD: 2%), pain (IR: PD: 8%), paresthesia (IR: RLS: 3%), sudden onset of sleep (IR; ER: ≤10%)<span class="lexi-table-link-container"> (<a aria-label="Sudden Onset of Sleep table link" class="lexi-table-link" data-table-id="lexi-content-sudden-onset-of-sleep" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sudden-onset-of-sleep')">table 8</a>)</span><span class="table-link" style="display:none;">Sudden Onset of Sleep</span>, vertigo (IR: PD, RLS: 2%), yawning (IR: PD: 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hallucination" frame="border" id="lexi-content-hallucination" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Hallucination</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">147</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sudden Onset of Sleep" frame="border" id="lexi-content-sudden-onset-of-sleep" rules="all">
<caption style="text-align:center;">
<b>Ropinirole: Adverse Reaction: Sudden Onset of Sleep</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Ropinirole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">39</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">24 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">41</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">13</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Early Parkinson disease</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (IR: RLS: 4%), hyperkinetic muscle activity (IR: PD: 2%), increased creatine phosphokinase in blood specimen (ER: 10%), limb pain (IR: RLS: 3%), muscle cramps (IR: RLS: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye disease (IR: PD: 3%), visual disturbance (IR: PD: 6%), xerophthalmia (IR: PD: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (IR: PD: 3%), cough (IR: RLS: 3%), dyspnea (IR: PD: 3%), nasal congestion (IR: RLS: 2%), nasopharyngitis (IR: RLS: 9%), pharyngitis (IR: PD: 6%), rhinitis (IR: PD: 4%), sinusitis (IR: PD: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Respiratory: Pleural effusion</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all indications and formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart valve disease (Andersohn 2009, Dewey 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation, behavioral problems, delirium, delusion, disorientation, falling (Kujawa 2000), impulse control disorder (including increased libido, pathological gambling) (Bastiaens 2013; Corvol 2018), mania, paranoid ideation, psychotic symptoms (Grover 2010), restless legs syndrome (IR: RLS: augmentation and/or early morning rebound) (García-Borreguero 2012, Rosenstein 2015), withdrawal syndrome (including anxiety, apathy, depression, insomnia) (Yu 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease, pleuropulmonary fibrosis (Andersohn 2009)</p></div>
<div class="block coi drugH1Div" id="F219129"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, urticaria, angioedema, rash, pruritus) to ropinirole or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F219115"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dyskinesias: May cause and/or exacerbate dyskinesias. Use with caution in patients with preexisting dyskinesias. Decreasing the dose may alleviate this condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have been associated with fibrotic complications (eg, pericarditis, retroperitoneal fibrosis, pleural effusion, pleural thickening, pulmonary infiltrates, cardiac valvulopathy). Although ropinirole is not an ergot, there have been postmarketing reports of possible fibrotic complications (pleural effusion, pleural fibrosis, interstitial lung disease, and cardiac valvulopathy) with ropinirole; monitor closely for signs and symptoms of fibrosis. Discontinuation of therapy may resolve complications, but not in all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal changes: Pathologic degenerative changes were observed in the retinas of albino rats during studies with this agent, but were not observed in the retinas of albino mice or in other species. The significance of these data for humans remains uncertain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease because of a risk for elevation in BP and changes in heart rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (extensively metabolized).</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychotic disorder: Avoid use in patients with a major psychotic disorder; may exacerbate symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extended release: ER ropinirole is designed to release medication over a 24-hour period. If rapid GI transit occurs, there may be risk of incomplete release of medication and medication residue being passed in the stool.</p></div>
<div class="block foc drugH1Div" id="F219124"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Requip XL: 6 mg [DSC], 8 mg [DSC], 12 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg, 6 mg, 8 mg, 12 mg</p></div>
<div class="block geq drugH1Div" id="F219111"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F219132"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (rOPINIRole HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.83 - $2.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $3.67 - $5.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg (per each): $5.50 - $8.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $5.50 - $8.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 mg (per each): $7.21 - $13.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (rOPINIRole HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $0.20 - $2.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $0.20 - $2.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.20 - $2.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.20 - $2.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $0.23 - $2.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.23 - $2.62</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.23 - $2.62</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868191"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg, 1 mg, 2 mg, 5 mg</p></div>
<div class="block adm drugH1Div" id="F6158752"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to meals. Swallow ER tablet whole; do not crush, divide, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block use drugH1Div" id="F219125"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease:</b> Treatment of Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (immediate release only):</b> Treatment of moderate to severe primary restless legs syndrome.</p></div>
<div class="block mst drugH1Div" id="F219181"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Requip may be confused with Reglan.</p>
<p style="text-indent:-2em;margin-left:4em;">ROPINIRole may be confused with RisperDAL, risperiDONE, ropivacaine.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F219167"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F219120"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Injection): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride (Oral). Amisulpride (Oral) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (First Generation [Typical]): Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Antipsychotic Agents (First Generation [Typical]) may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible. If antipsychotic use is necessary, consider using atypical antipsychotics such as clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider avoiding atypical antipsychotic use in patients with Parkinson disease. If an atypical antipsychotic is necessary, consider using clozapine, quetiapine, or ziprasidone at lower initial doses, or a non-dopamine antagonist (eg, pimavanserin).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Specifically, the risk of chorea may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the sedative effect of ROPINIRole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inducers (Moderate): May decrease the serum concentration of ROPINIRole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Moderate): May increase the serum concentration of ROPINIRole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP1A2 Inhibitors (Strong): May increase the serum concentration of ROPINIRole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of ROPINIRole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). Kava Kava may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May decrease the serum concentration of ROPINIRole.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F6158625"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of ropinirole for the treatment of restless legs syndrome in pregnant women is limited. Current guidelines note that the available information is insufficient to make a recommendation for use in pregnant women (Aurora 2012; Dostal 2013; Tüfekçioğlu 2018).</p></div>
<div class="block brc drugH1Div" id="F6158627"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ropinirole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Ropinirole inhibits prolactin secretion in humans and may potentially inhibit lactation. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F639157"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP (orthostatic); signs and symptoms of postural hypotension, especially during dose escalation (Parkinson patients); daytime alertness; CNS depression, fall risk, behavior changes (eg, compulsive behaviors); periodic skin examinations</p></div>
<div class="block pha drugH1Div" id="F219114"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ropinirole has a high relative <i>in vitro</i> specificity and full intrinsic activity at the D<sub>2</sub> and D<sub>3</sub> dopamine receptor subtypes, binding with higher affinity to D<sub>3</sub> than to D<sub>2</sub> or D<sub>4</sub> receptor subtypes; relevance of D<sub>3</sub> receptor binding in Parkinson disease is unknown. Ropinirole has moderate <i>in vitro</i> affinity for opioid receptors. Ropinirole and its metabolites have negligible <i>in vitro</i> affinity for dopamine D<sub>1</sub>, 5-HT<sub>1</sub>, 5-HT<sub>2</sub>, benzodiazepine, GABA, muscarinic, alpha<sub>1</sub>-, alpha<sub>2</sub>-, and beta-adrenoreceptors. Although precise mechanism of action of ropinirole is unknown, it is believed to be due to stimulation of postsynaptic dopamine D<sub>2</sub>-type receptors within the caudate putamen in the brain. Ropinirole caused decreases in systolic and diastolic blood pressure at doses &gt;0.25 mg. The mechanism of ropinirole-induced postural hypotension is believed to be due to D<sub>2</sub>-mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.</p></div>
<div class="block phk drugH1Div" id="F219128"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Immediate release: Rapid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 7.5 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 40%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic via CYP1A2 to inactive metabolites; first-pass effect </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Absolute: 45% to 55% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Immediate release: ~1-2 hours; Extended release: 6-10 hours; T<sub>max</sub> increased by 2.5-3 hours when taken with a high-fat meal  </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;10% as unchanged drug, 60% as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51159832"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance of ropinirole was reduced by ~30% in patients with ESRD on dialysis</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with hepatic impairment may have higher plasma levels and lower clearance of ropinirole</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Oral clearance is reduced ~15% in patients &gt;65 years</p>
<p style="text-indent:-2em;margin-left:2em;">Cigarette smoking: Clearance is expected to increase because CYP1A2 is known to be induced by smoking. C<sub>max</sub> was 30% and AUC was 38% lower in smokers compared with nonsmokers.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F219134"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Requip | Requip pd</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirol Actavis | Ropinirol Arcana | Ropinirol krka | Ropinirol Ratiopharm | Ropinirol sandoz | Ropinirol Stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Appese | Pharmacor ropinirole | Repreve | Ropaccord | Ropinirole ga</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ropinol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Requip | Requip modutab | Ropinirol Apotex | Ropinirol sandoz | Ropinirol Teva | Ropinirole eg</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Nervamat | Raponer | Requip</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Ropinirol | Ropinirol helvepharm | Ropinirol mepha | Ropinirol sandoz</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aropilo | Aropilos | Requip | Rolpryna | Ropinirol Actavis | Ropinirol farmax | Ropinirol orion | Ropinirol Teva | Ropinirole stada | Ropison</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Lepinole | Ralnea | Requip | Requip e m | Requip LP | Ropinal | Ropinirol 1 a pharma | Ropinirol AbZ | Ropinirol Acis | Ropinirol Actavis | Ropinirol AL | Ropinirol aurobindo | Ropinirol Billix | Ropinirol Biomo | Ropinirol CT | Ropinirol Dura | Ropinirol glenmark | Ropinirol heumann | Ropinirol Hexal | Ropinirol Hormosan | Ropinirol N | Ropinirol neuraxpharm | Ropinirol puren | Ropinirol Ratiopharm | Ropinirol Stada | Ropinirol TAD | Ropinirol Winthrop | Ropinirole dura | Ropinirole stada | Tifirol</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Valzorol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Requip | Rolpryna</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Tremodect</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Requip | Requip prolib | Rolpryna sr | Ropigen | Ropinirol aurobindo | Ropinirol Cinfa | Ropinirol Kern pharma | Ropinirol krka | Ropinirol Mylan | Ropinirol Normon | Ropinirol Ratiopharm | Ropinirol sandoz | Ropinirol Stada | Ropinirol Tarbis | Ropinirol Teva | Ropinirol vegal | Ropinirol Winthrop</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirol krka | Ropinirol Mylan | Ropinirol orion | Ropinirol Ratiopharm | Ropinirol sandoz | Ropinostad</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirole accord | Ropinirole Actavis | Ropinirole Arrow | Ropinirole biogaran | Ropinirole eg | Ropinirole Krka | Ropinirole mylan | Ropinirole Qualimed | Ropinirole sandoz | Ropinirole teva | Ropinirole Zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Aimpart XL | Eppinix XL | Ipinnia XL | Ralnea | Raponer | Repinex | Requip | Ropilynz xl | Ropinirole | Ropinirole Arrow | Ropinirole mylan | Ropiqual | Spiroco</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Ropinirole generics</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Eminens SR | Lirona XL | Requip | Ropinirol PharmaS</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aropilo | Ralnea | Requip | Ronipod | Ropidopin | Ropinirol Actavis | Ropinirol orion | Ropinirol Teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Requip pd</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Rolpryna | Rolpryna sr</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Parkirop | Ropark | Ropeway | Ropiro | Ropitor</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Lopiren | Requip | Rolpryna | Ropinirolo ahcl | Ropinirolo eg | Ropinirolo Ger | Ropinirolo mylan | Ropinirolo Sandoz | Ropiral</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirole | Ropinirole cr kyosomirai | Ropinirole cr towa | Ropinirole HCL</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dopapro | Doparopin | Hyundai ropinirole er | Newquip | Onirol | Pakinol | Pakinol pd | Parokin | Praquip | Requip | Requip pd | Rikirole | Rikirole pd | Rokins | Ropimax | Ropimax PD | Ropirino SR | Roquip</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alzorol | Requip | Rolpryna | Ropinirol orion | Ropitor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirol sandoz | Ropinirole eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alzorol | Requip | Requip prolib | Rolpryna | Ropinirol orion | Ropinirole orion</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ranpirole</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Parquip | Requip</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Ropinirol | Ropinirol Accord | Ropinirol Actavis | Ropinirol aurobindo | Ropinirol cf | Ropinirol Fisher | Ropinirol focus | Ropinirol glenmark | Ropinirol krka | Ropinirol Mylan | Ropinirol PCH | Ropinirol Ratiopharm | Ropinirol sandoz | Ropinirol Teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Ropinirol | Ropinirol Mylan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo ropinirole | Requip | Ropin | Ropinirole mylan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Requip pd</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Ralnea | Requip | Requip pd | Rinip | Ronirol | Ropinir | Ropinol | Xmg</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aparxon | Aropilo | Aropix | Ceurolex | Ceuronex | Nironovo | Parnirol | Polpix | Raponer | Repirol | Requip | Ropodrin | Valzorol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirole | Ropinirole HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Dopil | Requip | Ropinirol Actavis | Ropinirol Ciclum | Ropinirol Genedec | Ropinirol generis | Ropinirol krka | Ropinirol Labesfal | Ropinirol Mylan | Ropinirol Ratiopharm | Ropinirol sandoz | Ropinirol Teva | Ropinirol Wynn</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aleta | Requip | Rolpryna | Ropinirol Teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Requip | Sindranol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Adartrel | Requip | Requip ebb | Ropinirol 2care4 | Ropinirol abacus medicine | Ropinirol ebb | Ropinirol krka | Ropinirol Mylan | Ropinirol sandoz | Ropinirol Stada | Ropinirole orifarm | Ropinirole teva</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Requip | Ropinirole normon</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Repirol | Requip | Rolpryna</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aropilos | Aropix | Raponer | Requip | Rolipexa | Rolpryna | Ropinirol Actavis | Ropinirol farmax | Ropinirol krka | Ropinirol orion | Ropinstad | Ropison</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Requip pd</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Requip | Requip pd</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Rapinerol | Ropinirol orion</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Requip pd</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord ropinirole | Requip | Resure</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Requip</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Requip xl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19170199">
<a name="19170199"></a>Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. <i>Mov Disord</i>. 2009;24(1):129-133. doi:10.1002/mds.22385<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/19170199/pubmed" id="19170199" target="_blank">19170199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27425586">
<a name="27425586"></a>Antonini A, Chaudhuri KR, Boroojerdi B, et al. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>Eur J Neurol</i>. 2016;23(10):1556-1565. doi:10.1111/ene.13078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/27425586/pubmed" id="27425586" target="_blank">27425586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851801">
<a name="22851801"></a>Aurora RN, Kristo DA, Bista SR, et al, "The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults-An Update For 2012: Practice Parameters With an Evidence-Based Systematic Review and Meta-Analyses: An American Academy of Sleep Medicine Clinical Practice Guideline," <i>Sleep</i>, 2012, 35(8):1039-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/22851801/pubmed" id="22851801" target="_blank">22851801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31700703">
<a name="31700703"></a>Barone P, Antonini A, Stanzione P, Annoni K, Asgharnejad M, Bonuccelli U. Risk factors for impulse control disorders and related behaviors in Parkinson's disease: secondary analyses of the ICARUS study. <i>J Drug Assess</i>. 2019;8(1):159-166. doi:10.1080/21556660.2019.1675670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/31700703/pubmed" id="31700703" target="_blank">31700703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23283708">
<a name="23283708"></a>Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson's disease. <i>Mov Disord</i>. 2013;28(3):327-333. doi:10.1002/mds.25291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/23283708/pubmed" id="23283708" target="_blank">23283708</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9578193">
<a name="9578193"></a>Brefel C, Thalamas C, Rayet S, et al. Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients. <i>Br J Clin Pharmacol</i>. 1998;45(4):412-415. doi:10.1046/j.1365-2125.1998.t01-1-00704.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/9578193/pubmed" id="9578193" target="_blank">9578193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30713891">
<a name="30713891"></a>Chaudhuri KR, Todorova A, Nirenberg MJ, et al. A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson's disease. <i>Mov Disord Clin Pract</i>. 2015;2(2):170-174. doi:10.1002/mdc3.12141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/30713891/pubmed" id="30713891" target="_blank">30713891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29925549">
<a name="29925549"></a>Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. <i>Neurology</i>. 2018;91(3):e189-e201. doi:10.1212/WNL.0000000000005816<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/29925549/pubmed" id="29925549" target="_blank">29925549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31456212">
<a name="31456212"></a>Cutsforth-Gregory JK, Low PA. Neurogenic orthostatic hypotension in Parkinson disease: a primer. <i>Neurol Ther</i>. 2019;8(2):307-324. doi:10.1007/s40120-019-00152-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/31456212/pubmed" id="31456212" target="_blank">31456212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24078717">
<a name="24078717"></a>Demartini B, Ricciardi L, Ward A, Edwards MJ. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma. <i>J Neurol Neurosurg Psychiatry</i>. 2014;85(4):471. doi:10.1136/jnnp-2013-306043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/24078717/pubmed" id="24078717" target="_blank">24078717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17353380">
<a name="17353380"></a>Dewey RB 2nd, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. <i>Arch Neurol</i>. 2007;64(3):377-380. doi:10.1001/archneur.64.3.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/17353380/pubmed" id="17353380" target="_blank">17353380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083216">
<a name="23083216"></a>Dostal M, Weber-Schoendorfer C, Sobesky J, et al, "Pregnancy Outcome Following Use of Levodopa, Pramipexole, Ropinirole, and Rotigotine For Restless Legs Syndrome During Pregnancy: A Case Series," <i>Eur J Neurol</i>, 2013, 20(9):1241-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/23083216/pubmed" id="23083216" target="_blank">23083216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19515253">
<a name="19515253"></a>Ecker D, Unrath A, Kassubek J, Sabolek M. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. <i>BMC Neurol</i>. 2009;9:23. doi:10.1186/1471-2377-9-23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/19515253/pubmed" id="19515253" target="_blank">19515253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22993451">
<a name="22993451"></a>Edwards MJ. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'. <i>J Neurol Neurosurg Psychiatry</i>. 2013;84(2):120. doi:10.1136/jnnp-2012-303570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/22993451/pubmed" id="22993451" target="_blank">22993451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22328464">
<a name="22328464"></a>García-Borreguero D, Högl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. <i>Mov Disord</i>. 2012;27(2):277-283. doi:10.1002/mds.24889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/22328464/pubmed" id="22328464" target="_blank">22328464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28818004">
<a name="28818004"></a>Geyer J, Bogan R. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations. <i>Postgrad Med</i>. 2017;129(7):667-675. doi:10.1080/00325481.2017.1360747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/28818004/pubmed" id="28818004" target="_blank">28818004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24024727">
<a name="24024727"></a>Giannaki CD, Sakkas GK, Karatzaferi C, et al. Effect of exercise training and dopamine agonists in patients with uremic restless legs syndrome: a six-month randomized, partially double-blind, placebo-controlled comparative study. <i>BMC Nephrol</i>. 2013;14:194. doi:10.1186/1471-2369-14-194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/24024727/pubmed" id="24024727" target="_blank">24024727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33880737">
<a name="33880737"></a>Gossard TR, Trotti LM, Videnovic A, St Louis EK. Restless legs syndrome: contemporary diagnosis and treatment. <i>Neurotherapeutics</i>. 2021;18(1):140-155. doi:10.1007/s13311-021-01019-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/33880737/pubmed" id="33880737" target="_blank">33880737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28861870">
<a name="28861870"></a>Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: a complex association. <i>Drug Saf</i>. 2018;41(1):19-75. doi:10.1007/s40264-017-0590-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/28861870/pubmed" id="28861870" target="_blank">28861870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21494343">
<a name="21494343"></a>Grover S, Ghosh A. A case of ropinirole-induced psychosis. <i>Prim Care Companion J Clin Psychiatry</i>. 2010;12(6):PCC.10l00987. doi:10.4088/PCC.10l00987gre<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/21494343/pubmed" id="21494343" target="_blank">21494343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19249945">
<a name="19249945"></a>Hansen RA, Song L, Moore CG, et al. Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials. <i>Pharmacotherapy</i>. 2009;29(3):255-262. doi:10.1592/phco.29.3.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/19249945/pubmed" id="19249945" target="_blank">19249945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11798367">
<a name="11798367"></a>Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA</i>. 2002;287(4):455-463. doi:10.1001/jama.287.4.455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/11798367/pubmed" id="11798367" target="_blank">11798367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11069211">
<a name="11069211"></a>Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. <i>Clin Pharmacokinet</i>. 2000;39(4):243-254. doi:10.2165/00003088-200039040-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/11069211/pubmed" id="11069211" target="_blank">11069211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11030798">
<a name="11030798"></a>Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. <i>Arch Neurol</i>. 2000;57(10):1461-1463. doi:10.1001/archneur.57.10.1461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/11030798/pubmed" id="11030798" target="_blank">11030798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29383607">
<a name="29383607"></a>Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of nausea and vomiting in adults using ropinirole: a systematic review and meta-analysis. <i>Dig Dis Sci</i>. 2018;63(3):687-693. doi:10.1007/s10620-018-4937-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/29383607/pubmed" id="29383607" target="_blank">29383607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26765466">
<a name="26765466"></a>Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2016;95(2):e2504. doi:10.1097/MD.0000000000002504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/26765466/pubmed" id="26765466" target="_blank">26765466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23686524">
<a name="23686524"></a>Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. <i>Drugs Aging</i>. 2013;30(8):587-592. doi:10.1007/s40266-013-0090-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/23686524/pubmed" id="23686524" target="_blank">23686524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17404192">
<a name="17404192"></a>Pahwa R, Stacy MA, Factor SA, et al; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. <i>Neurology</i>. 2007;68(14):1108-1115. doi:10.1212/01.wnl.0000258660.74391.c1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/17404192/pubmed" id="17404192" target="_blank">17404192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987735">
<a name="16987735"></a>Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. <i>Lancet Neurol</i>. 2006;5(10):878-886. doi:10.1016/S1474-4422(06)70576-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/16987735/pubmed" id="16987735" target="_blank">16987735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319704">
<a name="15319704"></a>Pellecchia MT, Vitale C, Sabatini M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. <i>Clin Neuropharmacol</i>. 2004;27(4):178-181. doi:10.1097/01.wnf.0000135480.78529.06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/15319704/pubmed" id="15319704" target="_blank">15319704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16513886">
<a name="16513886"></a>Perea E, Robbins BV, Hutto B. Psychosis related to ropinirole. <i>Am J Psychiatry</i>. 2006;163(3):547-548. doi:10.1176/appi.ajp.163.3.547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/16513886/pubmed" id="16513886" target="_blank">16513886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20065130">
<a name="20065130"></a>Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. <i>Arch Neurol</i>. 2010;67(1):58-63. doi:10.1001/archneurol.2009.294<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/20065130/pubmed" id="20065130" target="_blank">20065130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10816186">
<a name="10816186"></a>Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>N Engl J Med</i>. 2000;342(20):1484-1491. doi:10.1056/NEJM200005183422004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/10816186/pubmed" id="10816186" target="_blank">10816186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21687750">
<a name="21687750"></a>Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and "on" time during different periods of the day and night in patients with advanced Parkinson's disease receiving adjunctive ropinirole prolonged release. <i>Parkinsons Dis</i>. 2011;2011:354760. doi:10.4061/2011/354760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/21687750/pubmed" id="21687750" target="_blank">21687750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GSK.1">
<a name="GSK.1"></a>Requip (ropinirole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GSK.2">
<a name="GSK.2"></a>Requip XL (ropinirole) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26106453">
<a name="26106453"></a>Rosenstein A, Rabin M, Kurlan R. Augmentation in restless legs syndrome: treatment with gradual medication modification. <i>Open Neurol J</i>. 2015;9:4-6. doi:10.2174/1874205X01509010004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/26106453/pubmed" id="26106453" target="_blank">26106453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9617508">
<a name="9617508"></a>Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. <i>Clin Neuropharmacol</i>. 1998;21(3):169-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/9617508/pubmed" id="9617508" target="_blank">9617508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Silber.1">
<a name="Silber.1"></a>Silber MH. Treatment of restless legs syndrome and periodic limb movement disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spindler.1">
<a name="Spindler.1"></a>Spindler MA. Initial pharmacologic treatment of Parkinson disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18768106">
<a name="18768106"></a>Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. <i>Curr Med Res Opin</i>. 2008;24(10):2883-2895. doi:10.1185/03007990802387130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/18768106/pubmed" id="18768106" target="_blank">18768106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Teva-Ropinirole (ropinirole) [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14707315">
<a name="14707315"></a>Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. <i>J Neurol Neurosurg Psychiatry</i>. 2004;75(1):92-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/14707315/pubmed" id="14707315" target="_blank">14707315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29926223">
<a name="29926223"></a>Tüfekçioğlu Z, Hanağası H, Yalçın Çakmaklı G, et al. Use of anti-Parkinson medication during pregnancy: a case series. <i>J Neurol</i>. 2018;265(8):1922-1929.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/29926223/pubmed" id="29926223" target="_blank">29926223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14725821">
<a name="14725821"></a>Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). <i>Sleep Med</i>. 2004;5(1):9-14. doi:10.1016/j.sleep.2003.07.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/14725821/pubmed" id="14725821" target="_blank">14725821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30363881">
<a name="30363881"></a>Yeung EYH, Cavanna AE. Sleep attacks in patients with Parkinson's disease on dopaminergic medications: a systematic review. <i>Mov Disord Clin Pract</i>. 2014;1(4):307-316. doi:10.1002/mdc3.12063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/30363881/pubmed" id="30363881" target="_blank">30363881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28104232">
<a name="28104232"></a>Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: a comprehensive review. <i>J Neurol Sci</i>. 2017;374:53-55. doi:10.1016/j.jns.2016.12.070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ropinirole-drug-information/abstract-text/28104232/pubmed" id="28104232" target="_blank">28104232</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10246 Version 489.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
